Principal Securities, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Principal Securities, Inc.
- $3.63 Trillion
- Q2 2024
A detailed history of Principal Securities, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 591 shares of APLS stock, worth $24,260. This represents 0.0% of its overall portfolio holdings.
Number of Shares
591
Previous 269
119.7%
Holding current value
$24,260
Previous $15.8 Million
43.38%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
113MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$673 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$476 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$456 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$403 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$238 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $4.51B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...